343 related articles for article (PubMed ID: 26796254)
1. Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction.
Wang TY; Vora AN; Peng SA; Fonarow GC; Das S; de Lemos JA; Peterson ED
J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26796254
[TBL] [Abstract][Full Text] [Related]
2. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction.
Hernandez AF; Mi X; Hammill BG; Hammill SC; Heidenreich PA; Masoudi FA; Qualls LG; Peterson ED; Fonarow GC; Curtis LH
JAMA; 2012 Nov; 308(20):2097-107. PubMed ID: 23188026
[TBL] [Abstract][Full Text] [Related]
3. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
Bauersachs J; Ertl G
Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569
[TBL] [Abstract][Full Text] [Related]
4. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
6. Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry.
Khazanie P; Liang L; Curtis LH; Butler J; Eapen ZJ; Heidenreich PA; Bhatt DL; Peterson ED; Yancy CW; Fonarow GC; Hernandez AF
Circ Heart Fail; 2016 Feb; 9(2):e002444. PubMed ID: 26867758
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction.
Patel K; Fonarow GC; Kitzman DW; Aban IB; Love TE; Allman RM; Gheorghiade M; Ahmed A
JACC Heart Fail; 2013 Feb; 1(1):40-7. PubMed ID: 23814702
[TBL] [Abstract][Full Text] [Related]
8. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure.
Cooper LB; Hammill BG; Peterson ED; Pitt B; Maciejewski ML; Curtis LH; Hernandez AF
Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28073850
[TBL] [Abstract][Full Text] [Related]
10. Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone.
Lam PH; Dooley DJ; Inampudi C; Arundel C; Fonarow GC; Butler J; Wu WC; Blackman MR; Anker MS; Deedwania P; White M; Prabhu SD; Morgan CJ; Love TE; Aronow WS; Allman RM; Ahmed A
Int J Cardiol; 2017 Jan; 227():462-466. PubMed ID: 27866868
[TBL] [Abstract][Full Text] [Related]
11. Use of aldosterone antagonists at discharge after myocardial infarction: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG).
Rao KK; Enriquez JR; de Lemos JA; Alexander KP; Chen AY; McGuire DK; Fonarow GC; Das SR
Am Heart J; 2013 Oct; 166(4):709-15. PubMed ID: 24093851
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
13. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction.
Rassi AN; Cavender MA; Fonarow GC; Cannon CP; Hernandez AF; Peterson ED; Peacock WF; Laskey WK; Rosas SE; Zhao X; Schwamm LH; Bhatt DL
J Am Coll Cardiol; 2013 Jan; 61(1):35-40. PubMed ID: 23137936
[TBL] [Abstract][Full Text] [Related]
14. Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure.
Löfman I; Szummer K; Olsson H; Carrero JJ; Lund LH; Jernberg T
J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 29980521
[TBL] [Abstract][Full Text] [Related]
15. Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Beygui F; Cayla G; Roule V; Roubille F; Delarche N; Silvain J; Van Belle E; Belle L; Galinier M; Motreff P; Cornillet L; Collet JP; Furber A; Goldstein P; Ecollan P; Legallois D; Lebon A; Rousseau H; Machecourt J; Zannad F; Vicaut E; Montalescot G;
J Am Coll Cardiol; 2016 Apr; 67(16):1917-27. PubMed ID: 27102506
[TBL] [Abstract][Full Text] [Related]
16. Guideline-Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient-Pooled Analysis From the Kor HF and Kor AHF Registries.
Choi KH; Choi JO; Jeon ES; Lee GY; Choi DJ; Lee HY; Kim JJ; Chae SC; Baek SH; Kang SM; Yoo BS; Kim KH; Cho MC; Park HY; Oh BH
J Am Heart Assoc; 2018 Nov; 7(21):e009806. PubMed ID: 30608208
[TBL] [Abstract][Full Text] [Related]
17. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
[TBL] [Abstract][Full Text] [Related]
18. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
Cunningham JW; Vaduganathan M; Claggett BL; John JE; Desai AS; Lewis EF; Zile MR; Carson P; Jhund PS; Kober L; Pitt B; Shah SJ; Swedberg K; Anand IS; Yusuf S; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2020 Aug; 8(8):618-626. PubMed ID: 32387067
[TBL] [Abstract][Full Text] [Related]
19. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).
Luo N; Fonarow GC; Lippmann SJ; Mi X; Heidenreich PA; Yancy CW; Greiner MA; Hammill BG; Hardy NC; Turner SJ; Laskey WK; Curtis LH; Hernandez AF; Mentz RJ; O'Brien EC
JACC Heart Fail; 2017 Apr; 5(4):305-309. PubMed ID: 28359417
[TBL] [Abstract][Full Text] [Related]
20. Predictors of the Use of Mineralocorticoid Receptor Antagonists in Patients With Left Ventricular Dysfunction Post-ST-Segment-Elevation Myocardial Infarction.
Wong EC; Fordyce CB; Wong G; Lee T; Perry-Arnesen M; Mackay M; Singer J; Cairns JA; Turgeon RD
J Am Heart Assoc; 2021 Jul; 10(14):e019167. PubMed ID: 34227405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
